Back to search

Article

Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants

2022-04-10

Abstract excerpt

The B.1.1.529 (omicron) variant has rapidly supplanted most other SARS-CoV-2 variants. Using microfluidics-based antibody affinity profiling (MAAP), we have recently shown that current therapeutic monoclonal antibodies exhibit a drastic loss of affinity against omicron. Here, we have characterized affinity and IgG concentration in the plasma of 39 individuals with multiple trajectories of SARS-CoV-2 infection and/...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bdc4f1e9-3971-5101-827a-9501b8c59612
DOI
10.1101/2022.04.07.22273545
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variantsDOI 10.1101/2022.04.07.22273545
Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variantsSemantic proximity
Serum proteomics reveals high-affinity and convergent antibodies by tracking SARS-CoV2 hybrid immunity to emerging variants of concernSemantic proximity
Shared N417-dependent epitope on the SARS-CoV-2 Omicron, Beta and Delta-plus variantsSemantic proximity
SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope.Semantic proximity
Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD-20 therapySemantic proximity
IgG1 responses following SARS-CoV-2 infection are polyclonal and highly personalized, whereby each donor and each clone displays a distinct pattern of cross-reactivity against SARS-CoV-2 variantsSemantic proximity
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)Semantic proximity
Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virusSemantic proximity
Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individualsSemantic proximity
SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and OmicronSemantic proximity
A High-Throughput Broad Neutralizing Antibody Assay for Detecting SARS-CoV-2 Variant Immunity in PopulationSemantic proximity
Production of a monoclonal antibody targeting the SARS-CoV-2 Omicron spike protein and analysis of SARS-CoV-2 Omicron mutations related to monoclonal antibody resistance.Semantic proximity
Select a neighboring publication to make it the new centre.